Skip to content

Ranked by human evidence

Best Peptides for Brain and Focus, Ranked by Human Evidence

The best-evidenced brain peptides are rated limited, and 4 tie at that level: Pinealon, Selank, Semax and Cerebrolysin. Cerebrolysin has the largest trial record, with mixed results in stroke and dementia, and I found no published human trial of Dihexa or PE-22-28.

Semax and Selank show cognitive and mood effects in mostly older Russian studies; rigorous modern human trials are lacking. Both are research-use-only, not approved for human use.

Related: Semax vs Selank · Peptides for ADHD · Peptides for sleep

Peptides for brain and focus, ranked by human evidence

The order is the strength of human evidence, strongest first: strong, moderate, limited, animal or lab only, then none. Ties keep the site's usual compound order. A higher rank means more and better human studies, not that a compound works for brain and focus, so check what each study measured.

Peptides for brain and focus compared: evidence level, US legal status and what human studies measured
RankCompoundEvidenceUS statusMeasured in humansGuide
1PinealonLimited human dataResearch use onlyPsychological and biological-age scores in small Russian studies with no placebo group described.Read
2SelankLimited human dataResearch use only2 controlled trials in Russian-language journals, about a decade old and not independently replicated.Read
3SemaxLimited human dataResearch use onlyA handful of Russian clinical studies in people with diagnosed conditions; none I found in healthy adults for cognition.Read
4CerebrolysinLimited human dataUnapproved drugAcute stroke and vascular dementia in Cochrane-reviewed trials: no survival benefit in stroke, a weak-evidence benefit in dementia.Read
5DihexaAnimal / lab onlyResearch use onlyNone: FDA found no human exposure data by any route.Read
6CortagenAnimal / lab onlyResearch use onlyCell and animal studies only; no controlled human trials.Read
7PE-22-28Animal / lab onlyUnapproved drugNone: every figure comes from mouse studies.Read
8AdamaxNo meaningful evidenceUnapproved drugNone: I found no published research on it in any language.Read
  1. Research peptidesResearch use only

    1. Pinealon

    Limited human data

    Measured in humans: Psychological and biological-age scores in small Russian studies with no placebo group described.

    Why this rating

    Twenty-two PubMed records in total, one tagged as a clinical trial and none as a randomised controlled trial. Several records returned under a human-tagged search are false positives about unrelated subjects. Most of what exists is mechanistic laboratory work; the four human studies in my registry are small Russian reports (150 lorry drivers and locomotive crews in 2012, about 30 adults in 2015, 110 people in 2016) whose abstracts describe no placebo group; the only stated dose is 100 mcg by mouth twice daily for two weeks, and the 2015 study reported pro-oxidant activity and a fall in blood stem cells.

  2. Research peptidesResearch use only

    2. Selank

    Limited human data

    Measured in humans: 2 controlled trials in Russian-language journals, about a decade old and not independently replicated.

    Why this rating

    Of 135 PubMed records, 33 are Russian-language and six are tagged as clinical trials. Of three tagged as randomised, one is a muscular strength and hypertrophy paper that appears to be a false positive, leaving two Russian-language papers from 2008 and 2015.

  3. Research peptidesResearch use only

    3. Semax

    Limited human data

    Measured in humans: A handful of Russian clinical studies in people with diagnosed conditions; none I found in healthy adults for cognition.

    Why this rating

    Of 231 PubMed records, 105 are Russian-language, four are tagged as clinical trials and one as a randomised controlled trial - itself Russian-language, from 2007, concerning chronic partial denervation rather than the marketed cognitive use.

  4. Research peptidesUnapproved drug

    4. Cerebrolysin

    Limited human data

    Measured in humans: Acute stroke and vascular dementia in Cochrane-reviewed trials: no survival benefit in stroke, a weak-evidence benefit in dementia.

    Why this rating

    Cerebrolysin has an unusually large human trial record for a compound this site covers, including multiple randomised controlled trials and two current Cochrane systematic reviews. That record does not agree with itself: the 2023 Cochrane review of cerebrolysin for acute ischaemic stroke, covering 7 RCTs, found moderate-certainty evidence of no benefit on preventing death and a possible increase in non-fatal serious adverse events. Separately, one randomised trial in early stroke rehabilitation (not the acute-stroke setting the Cochrane review covers) reported a benefit on motor function and global outcome, describing itself as exploratory and calling for larger confirmatory trials. The 2019 Cochrane review of cerebrolysin for vascular dementia, covering 6 RCTs and 597 participants, reported a cognition and function benefit but called the evidence base weak and at high risk of bias. Read together: real trial-level evidence exists, it is mixed by indication, and the highest-quality synthesis (Cochrane, acute stroke) is negative on its primary outcome. Full citations on the guide page.

  5. Research peptidesResearch use only

    5. Dihexa

    Animal / lab only

    Measured in humans: None: FDA found no human exposure data by any route.

    Why this rating

    A PubMed search for dihexa (queried 24 September 2026) returns 18 records and zero indexed under a clinical-trial or randomised-controlled-trial publication type. FDA's bulk drug substances safety-risk page states it has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration. Published work is preclinical: cell and animal research, not human trials.

  6. Research peptidesResearch use only

    6. Cortagen

    Animal / lab only

    Measured in humans: Cell and animal studies only; no controlled human trials.

    Why this rating

    Every study of Cortagen I located and read is an animal experiment - a gene-expression microarray in mouse heart tissue and a behavioural/biochemical study in ischemic rat brains - from Russian research groups working in the same peptide-bioregulator tradition. One of the papers I read states, as background rather than as its own finding, that Cortagen showed a therapeutic effect on human peripheral-nerve recovery after injury; I could not independently locate and verify that human claim as a primary trial.

  7. Research peptidesUnapproved drug

    7. PE-22-28

    Animal / lab only

    Measured in humans: None: every figure comes from mouse studies.

    Why this rating

    One published study describes PE 22-28 directly: in vitro channel-binding assays plus mouse behavioral testing (forced swimming, novelty-suppressed feeding) and neurogenesis markers after 4 days of treatment. All of it is animal and cell-culture data. A PubMed search for PE-22-28 in humans returns no results, and no Phase 1 safety study has been conducted or published for any species beyond mice. That keeps this at the lowest evidence tier this site uses: real preclinical data exists, but nothing has been tested in a person.

  8. Research peptidesUnapproved drug

    8. Adamax

    No meaningful evidence

    Measured in humans: None: I found no published research on it in any language.

    Why this rating

    A PubMed search for "Adamax" returns no results, and unlike its parent compound Semax - which at least has a body of Russian-language clinical literature - I could not locate any published research, in any language, specific to Adamax. It does not appear in PubChem or in any CAS registry I could verify. The chemical structure itself is inconsistently described across the vendors that sell it - see the mechanism field - which is a more basic problem than an evidence gap: there is no confirmed, agreed identity for what is being sold under this name, let alone a study of it.

Common questions about peptides for brain and focus

What is the best peptide for the brain?

I found none with strong human evidence for focus or memory in healthy adults. Four tie on limited human data: Pinealon, Selank, Semax and Cerebrolysin. Semax and Selank are used clinically in Russia, but their human trials are few, small and mostly in Russian-language journals.

What peptide is best for brain repair?

Cerebrolysin has the most trials, in stroke and vascular dementia. Cochrane's review of acute stroke found no survival benefit and a probable rise in serious side effects; a separate review found a modest, weak-evidence benefit in vascular dementia. It is a prescription drug in dozens of countries, but not FDA-approved.

Do Semax and Selank work?

Their human evidence is real but narrow. Selank has 2 controlled trials in Russian-language journals, about a decade old and not independently replicated. Semax has a handful of Russian clinical studies in people with specific diagnosed conditions, and I found none that tested the healthy-adult cognitive use it is sold for.

Can BPC-157 be used to treat dementia?

I found no study of BPC-157 in dementia. Its 5 small human studies cover ulcerative colitis, a safety study in healthy volunteers, knee pain, interstitial cystitis and a 2-person intravenous report. Almost all of its efficacy data comes from rats.

Is Dihexa safe?

I found no published human trial. FDA says it found no human exposure data on dihexa acetate by any route, and lacks the information to know whether it would harm people.

What are the downsides of brain peptides?

Semax, Selank, Dihexa and PE-22-28 are sold in the US as research chemicals, so no regulator checks a vial's identity, purity or sterility. Their human safety data are small, and I found none for Dihexa or PE-22-28. Cerebrolysin has the most data, and Cochrane's review of acute stroke found it probably increases non-fatal serious adverse events without reducing deaths.

Guides on peptides for brain and focus

Best peptides for other goals